Shah Mona Naman, Thomas Vinotha, Joel Anjana, Karuppusami Reka, Thomas Dhanya Susan, Sebastian Ajit, Thomas Anitha, Chandy Rachel, Peedicayil Abraham
Department of Gynaecologic Oncology, Christian Medical College, Vellore 632004, India.
https://orcid.org/0009-0005-2019-7132.
Ecancermedicalscience. 2024 Sep 16;18:1769. doi: 10.3332/ecancer.2024.1769. eCollection 2024.
To retrospectively describe the clinicopathological profile and treatment outcome of sex cord ovarian tumours (SCOTs), from a single institution.
Patients who operated for SCOT between January 2011 and December 2020 were identified from the institution's discharge summaries. Treatment details and oncologic outcomes were analyzed using descriptive statistics, SPSS statistics version 21. Progression-free survival and overall survival were plotted using the Kaplan-Meier method.
Over 10 years, 120 patients underwent surgery with 73 (61%) malignant SCOTs. Eight (6.6%) were referred with recurrence. Granulosa cell histology (61/73, 83.5%) and federation of gynaecology and obstetrics (FIGO) stage I disease (57/65, 78.62%) were predominant. Three (3/26,11.53%) had lymph node involvement. Adjuvant chemotherapy was advised in 53.4% (39/73).Over a median period of 47 months (1-130 months), eleven (15.06%) patients recurred (5-year recurrence rate: 9.58%) and 6 died (5-year survival rate: 89.04%).Among 65 patients with upfront disease, 9 (13.8%) recurred over a median period of 46 months (1-65 months) with 4 disease-related deaths. On univariate analysis, incomplete cytoreduction hazard ratios (HR 58.391, 95% CI 5.042-674.854), advanced FIGO stage (HR 15.931, 3.74-67.89) and nongranulosa histology was associated with recurrence. On multivariate analysis, advanced FIGO stage (HR 20.099, 95% CI 3.75-107.711) and non granulosa histology (HR 31.35, 95% 2.801-350.897 ) remained significant. Lymphadenectomy and adjuvant chemotherapy did not prevent recurrence.
回顾性描述来自单一机构的性索卵巢肿瘤（SCOTs）的临床病理特征及治疗结果。
从该机构的出院总结中确定2011年1月至2020年12月期间接受SCOT手术的患者。使用描述性统计方法（SPSS统计软件21版）分析治疗细节和肿瘤学结果。采用Kaplan-Meier法绘制无进展生存期和总生存期曲线。
在10多年间，120例患者接受了手术，其中73例（61%）为恶性SCOTs。8例（6.6%）患者复发时前来就诊。颗粒细胞瘤组织学类型（61/73，83.5%）和国际妇产科联盟（FIGO）I期疾病（57/65，78.62%）最为常见。3例（3/26，11.53%）有淋巴结受累。53.4%（39/73）的患者建议接受辅助化疗。在中位时间47个月（1 - 130个月）内，11例（15.06%）患者复发（5年复发率：9.58%），6例死亡（5年生存率：89.04%）。在65例初治患者中，9例（13.8%）在中位时间46个月（1 - 65个月）内复发，4例死于疾病相关原因。单因素分析显示，细胞减灭不完全（风险比[HR] 58.391，95%置信区间[CI] 5.042 - 674.854）、FIGO晚期（HR 15.931，3.74 - 67.89）和非颗粒细胞瘤组织学与复发相关。多因素分析显示，FIGO晚期（HR 20.099，95% CI 3.75 - 107.711）和非颗粒细胞瘤组织学（HR 31.35，95% CI 2.801 - 350.897）仍然具有显著性。淋巴结清扫术和辅助化疗未能预防复发。
